Lyell Immunopharma (LYEL) Income towards Parent Company (2020 - 2026)
Lyell Immunopharma recorded quarterly Income towards Parent Company of -$42.1 million in Q1 2026, up 66.34% quarter-over-quarter from -$125.0 million in Q4 2025, and up 21.38% year-over-year from -$34.7 million in Q1 2025.
Lyell Immunopharma's Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$42.1 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 21.38% year-over-year to -$42.1 million; the TTM figure through Mar 2026 stood at -$244.9 million (up 27.86% YoY), while the FY2025 annual figure was -$256.3 million, up 23.41% from the prior year.
- Income towards Parent Company came in at -$42.1 million for Q1 2026 at Lyell Immunopharma, up from -$125.0 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$11.3 million in Q4 2022 to a low of -$196.2 million in Q4 2024.
- A 5-year average of -$61.0 million and a median of -$52.4 million in 2023 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company soared 76.0% in 2022 and tumbled 362.66% in 2023, its largest moves.
- Lyell Immunopharma's Income towards Parent Company stood at -$11.3 million in 2022, then sank by 362.66% to -$52.4 million in 2023, then slumped by 274.31% to -$196.2 million in 2024, then jumped by 36.31% to -$125.0 million in 2025, then surged by 66.34% to -$42.1 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$42.1 million, -$125.0 million, and -$34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Lyell Immunopharma | 373.31 Mn | 373.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.07 Mn |
| Dec 31, 2025 | -124.97 Mn |
| Sep 30, 2025 | -33.99 Mn |
| Jun 30, 2025 | -43.86 Mn |
| Mar 31, 2025 | -53.51 Mn |
| Dec 31, 2024 | -196.23 Mn |
| Sep 30, 2024 | -44.54 Mn |
| Jun 30, 2024 | -45.16 Mn |
| Mar 31, 2024 | -48.76 Mn |
| Dec 31, 2023 | -52.42 Mn |
| Sep 30, 2023 | -52.43 Mn |
| Jun 30, 2023 | -60.64 Mn |
| Mar 31, 2023 | -58.06 Mn |
| Dec 31, 2022 | -11.33 Mn |
| Sep 30, 2022 | -64.19 Mn |
| Jun 30, 2022 | -36.31 Mn |
| Mar 31, 2022 | -68.18 Mn |
| Dec 31, 2021 | -47.22 Mn |
| Sep 30, 2021 | -48.89 Mn |
| Jun 30, 2021 | -62.49 Mn |
| Mar 31, 2021 | -55.02 Mn |
| Dec 31, 2020 | -38.90 Mn |
| Sep 30, 2020 | -35.75 Mn |
| Jun 30, 2020 | -100.69 Mn |